CTKB — Q2 2026 Financial Report Analysis

Cytek Biosciences, which makes spectral flow cytometers (lab instruments that count and sort individual cells by the light patterns they give off), grew second-quarter 2026 revenue 6% to $48.1 million. US instrument sales and service contracts drove the gain, while Europe and Latin America declined. The quarter looks better than it is. Gross margin jumped to 59%, but a one-time $2.8 million tariff refund accounts for most of that. Without the refund, operating losses would have widened. The net loss more than doubled to $12.2 million, mainly because last year's quarter had foreign-exchange gains and a tax benefit that this year's didn't. The bigger story came after the quarter closed: on August 21 a jury awarded rival Beckman Coulter $56 million in a patent case. That is about a fifth of Cytek's $262 million cash pile.

At a glance

• US revenue rose 18% to $28.2 million, while Europe/Middle East/Africa fell 8% to $11.3 million. Cytek's growth now depends on one region.
• The 59% gross margin falls to about 53% without the tariff refund. Gross margin is the share of revenue left after the direct cost of making and servicing products. On that like-for-like basis it improved by only about one point from 52% a year ago.
• Net loss of $0.09 per share versus $0.04. Most of the gap sits below the operating line: a $0.7 million currency loss replaced a $1.6 million gain, Cytek wrote off a $1.6 million startup investment, and a $1.2 million tax benefit became a $0.5 million charge.

The numbers

Source: Cytek's Form 10-Q for the quarter ended June 30, 2026, and its August 5 earnings release. Adjusted EBITDA is earnings before interest, tax, depreciation and amortization. The company's version also excludes stock-based pay, currency effects and the investment write-off.

Where the growth came from, and where it didn't

Cytek sells in two ways. It sells instruments once, for hundreds of thousands of dollars each. Then it earns repeat revenue from service contracts and the reagents (chemical stains) customers use in every experiment. Both showed up this quarter:

• Instruments in the US. The 10-Q says product revenue growth was "primarily due to growth of instrument revenue in the United States, partially offset by lower instrument revenue in the EMEA, Rest of World, and APAC markets." US revenue rose $4.3 million year over year, which is more than the company's total increase of $2.5 million. Outside the US, revenue fell. Asia-Pacific was flat at $7.9 million. Within it, China brought in $4.8 million, and management called China instrument growth "strong double-digit." The "Other" region (Canada and Latin America) fell from $1.5 million to $0.7 million.
• Service. Service revenue grew 10% "primarily due to continued growth of the installed base." That means more instruments in the field and more maintenance contracts. Service gross margin improved to 56% from 52% because of lower service material costs. Total recurring revenue (service plus reagents) was $18.5 million. Over the past 12 months it made up 35% of revenue, up from 32% a year earlier. Recurring revenue matters because it keeps coming in when lab budgets freeze and instrument purchases stall.

The quarter also brought two new instruments. Cytek launched Borealis, a 7-laser analyzer that can measure up to 60 colors, and introduced automation-ready configurations of Aurora Evo. Neither had time to contribute much revenue yet.

What the headline numbers hide

• The margin jump is mostly a refund. In February 2026 the US Supreme Court struck down tariffs imposed under the International Emergency Economic Powers Act. Cytek applied for refunds and booked a one-time $2.8 million reduction in cost of goods sold. Without it, product gross margin was 52% (versus 53% a year ago, so slightly worse) and total gross margin was 53%. The underlying product margin also absorbed "higher material costs, inventory reserves and scrap expenses," per the 10-Q.
• Costs grew nearly three times as fast as revenue. Operating expenses rose 15% against 6% revenue growth. General and administrative costs rose 24% to $16.8 million, "primarily due to higher litigation-related expenses, and higher severance and other personnel costs." The patent case went to trial in August, so legal costs were heavy all quarter. The severance follows a run of executive departures: the head of global sales and service resigned in June, and the chief legal officer's role ended June 29. That is awkward timing, two months before a patent trial. Sales and marketing costs also included severance.
• Most of the wider net loss is below the operating line. Pre-tax loss widened by $4.9 million. Of that, $4.5 million came from "other income" swinging from +$3.7 million to -$0.8 million. That swing combines currency losses, the $1.6 million impairment on "a non-marketable equity investment in an early-stage technology company," and lower investment income. On top of that, a $1.2 million tax benefit became a $0.5 million charge. The tax change has a lasting cause: Cytek set up a "domestic valuation allowance" in late 2025. In plain terms, it no longer books a tax benefit on US losses because it isn't confident it will earn enough profit to use them. The currency and impairment pieces are noise. The tax change will keep weighing on reported losses.
• Cash flow looks better than the losses, partly because of seasonal collections. Over the first half, operating cash flow (cash actually generated by the business) was -$1.4 million against a $31.0 million net loss. Two things closed the gap. First, $10.2 million of the expenses was stock-based pay, which costs no cash. Second, an $11.6 million drop in receivables (customer bills collected), which the 10-Q attributes to seasonality: big fourth-quarter sales are collected in the first half. That second source won't repeat every half-year. Cash and marketable securities were $262.0 million, essentially unchanged from March's $262.2 million. In the first half Cytek also drew $5.1 million on a credit line and repaid $2.5 million of loans.
• Inventory is creeping up. Inventory rose to $52.3 million from $48.4 million in December (+8% in six months), while first-half revenue grew 6% year over year. With two new instruments launching, some build-up is understandable. Still, the 10-Q itself points to higher inventory reserves and scrap, so this is worth watching.
• Guidance edged up at the bottom end. Full-year 2026 revenue guidance moved to $207–212 million from $205–212 million in May, which lifts the midpoint by $1 million. First-half revenue was $92.3 million, so the guidance needs $114.7–119.7 million in the second half. That is a 24–30% step-up over the first half, which is normal for a business whose customers spend their budgets late in the year. The top of the range didn't move, though.

Takeaway: Without the one-time tariff refund, Cytek's operating loss would have been about $14.2 million (roughly -30% of revenue) versus $10.6 million a year earlier. Costs from litigation and management turnover are growing faster than sales. Then, after the quarter, a jury awarded Beckman Coulter $56 million. Cytek has the cash to absorb that, but the money would come straight out of its main cushion while the business is still losing money.

The patent verdict

Beckman Coulter sued in August 2024, claiming that Cytek's Aurora, Aurora CS and Northern Lights instruments (the core of its product line) infringe its "Flow Cytometer" patents. On August 21, 2026, the Delaware jury sided with Cytek on three of the four claims, finding them not infringed and invalid. On the fourth claim it found no literal infringement but found infringement under the "doctrine of equivalents." That legal doctrine covers a product that does essentially the same thing in essentially the same way, even if it doesn't match the patent's exact wording. The jury awarded $20 million in lost profits plus $36 million in royalties for past sales.

Cytek says the verdict "does not require any changes to the Company's current product offerings or operations." It plans post-trial motions and possibly an appeal to the Federal Circuit. The 10-Q was filed before the trial, and its legal note did not disclose any accrual for the case (an amount set aside for an expected loss). The damages cover past sales only. The press release doesn't say whether Beckman will seek ongoing royalties or an injunction (a court order to stop selling), and that is the larger long-term question.

What to watch

Cytek's third-quarter results are due in early November. Three things will show which direction the business is heading:

1. How the verdict is accounted for. Watch whether Cytek books a liability for some or all of the $56 million, which would hit reported earnings, and whether the court rules on its post-trial motions.
2. Margin without the refund. Q3 won't include the tariff refund. If gross margin stays near 53% or better while the two new instruments ramp, the underlying business is holding. A drop back toward 50% would mean the material-cost and scrap pressures are winning.
3. Whether Europe stabilizes and the second-half ramp shows up. The guidance assumes a strong second half, and the only region growing strongly right now is the US, where academic labs remain exposed to changes in NIH (National Institutes of Health) grant policy that the 10-Q itself flags.

Our view: the parts of the business that matter long term are moving the right way. The installed base and recurring revenue keep growing, and service margins improved. But this quarter's headline margin was flattered by a refund, overhead is growing faster than sales, and a $56 million legal exposure now hangs over the cash balance. A clean Q3 would need underlying gross margin above 53% and G&A falling once trial costs end. Until both show up, read the 6% growth as steady but expensive.